Reneo Pharma Reports Exit/Disposal Costs, Signals Strategic Shift
Ticker: OKUR · Form: 8-K · Filed: Feb 23, 2024 · CIK: 1637715
Sentiment: neutral
Topics: restructuring, corporate-action, operational-change
TL;DR
**Reneo Pharma is reporting costs tied to exiting or disposing of activities, signaling a major operational shift.**
AI Summary
Reneo Pharmaceuticals, Inc. filed an 8-K on February 23, 2024, reporting an event on February 20, 2024, related to costs associated with exit or disposal activities. The filing indicates the company is undergoing significant operational changes, potentially involving a restructuring or winding down of certain operations. This suggests a strategic shift for the Delaware-incorporated pharmaceutical preparations company, which has its business address at 18575 Jamboree Road, Suite 275-S, Irvine, California.
Why It Matters
This filing indicates Reneo Pharmaceuticals is undergoing significant operational changes, which could impact its future drug development, financial stability, and workforce.
Risk Assessment
Risk Level: medium — The filing indicates costs associated with exit or disposal activities, which can be a precursor to significant restructuring, asset sales, or even winding down operations, introducing uncertainty.
Key Players & Entities
- Reneo Pharmaceuticals, Inc. (company) — Registrant
- February 20, 2024 (date) — Date of earliest event reported
- February 23, 2024 (date) — Filing date
- Delaware (company) — State of Incorporation
- Irvine, California (company) — Business address location
FAQ
What is the purpose of this 8-K filing by Reneo Pharmaceuticals, Inc.?
The 8-K filing by Reneo Pharmaceuticals, Inc. is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically reporting on 'Cost Associated with Exit or Disposal Activities' as of February 20, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 20, 2024.
What is the full business address of Reneo Pharmaceuticals, Inc. as stated in the filing?
The full business address of Reneo Pharmaceuticals, Inc. is 18575 Jamboree Road, Suite 275-S, Irvine, California, 92612.
What is Reneo Pharmaceuticals, Inc.'s state of incorporation?
Reneo Pharmaceuticals, Inc. is incorporated in Delaware.
What is the Registrant's telephone number?
The Registrant's telephone number is 858 283-0280.
Filing Stats: 738 words · 3 min read · ~2 pages · Grade level 14.1 · Accepted 2024-02-23 16:00:15
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share RPHM The Nasdaq Stock Mar
- $1.7 million — it will incur charges of approximately $1.7 million associated with cash severance payments
Filing Documents
- rphm-20240220.htm (8-K) — 45KB
- 0000950170-24-019338.txt ( ) — 167KB
- rphm-20240220.xsd (EX-101.SCH) — 31KB
- rphm-20240220_htm.xml (XML) — 5KB
05 Costs Associated with Exit or Disposal Activities
Item 2.05 Costs Associated with Exit or Disposal Activities. As part of the plan of implementing cost saving initiatives announced by Reneo Pharmaceuticals, Inc. (the "Company") on December 14, 2023, the Company expects to complete a second workforce reduction of approximately 20% on February 29, 2024 (the "Second Reduction"). In connection with the Second Reduction, the Company estimates that it will incur charges of approximately $1.7 million associated with cash severance payments and other employee termination-related costs in the first quarter of 2024. The estimated charges that the Company expects to incur in connection with the Second Reduction, and the timing thereof, are subject to a number of assumptions, and actual amounts and timing may differ materially from these estimates. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the implementation of the Second Reduction.
Forward-Looking Statements
Forward-Looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Reneo Pharmaceuticals, Inc. Date: February 23, 2024 By: /s/ Gregory J. Flesher Gregory J. Flesher President and Chief Executive Officer (Principal Executive Officer)